Warnings for dopamine agonist drugs are to be reviewed after BBC identified an error in patient leaflets.

Sustainability has become a core consideration in pharmaceutical manufacturing. It is driven by evolving global regulations, consumer expectations, and increasingly complex supply chains, which all ...

Menopause drug Elinzanetant cuts hot flush frequency and severity in breast cancer patients on any hormone therapy, providing a safer, non-hormonal relief.

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting ...

For years, Metformin has been widely regarded as the frontline treatment for Type 2 Diabetes, trusted, cost-effective and largely safe. However, emerging research is now challenging that long-held ...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...

On 27 March, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK, hereinafter referred to as "Ausnutria" or the "Company") officially released its 2025 annual results announcement. According to the ...

On March 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its audited annual results for the year ended 31 December 2025 (the "Reporting Period"). During the Reporting ...